tbuckley/cabot-search huggingface dataset:
Abstract 15142: Left Bundle Branch Pacing, Procedure Characteristics, Feasibility and Long-term Safety: Insights From a Large Sample Single Center Study
Authors: Weijian Huang, Lan Su, Songjie Wang, Shengjie Wu, Lei Xu, Rujie Zheng, Limeng Jiang
Journal: Circulation (2020)

Introduction: Left bundle branch pacing (LBBP) is a novel pacing method and has been proven to have low and stable pacing thresholds. However, data on large numbers of patients with long-term follow-up is still needed to evaluate its feasibility and safety. Hypothesis: To evaluate the feasibility and safety of LBBP in a large sample with long-term follow up. Methods: This study prospectively enrolled 632 consecutive patients with left bundle branch block, AV block or sick sinus syndrome with attempted LBBP from April 2017 to July 2019. Pacing parameters, ECG, echocardiographic measurements, complications were assessed at implant, and during follow-up of 1, 6, 12 and 24 months. Results: LBBP was successful in 618/632 (97.8%) patients according to the strict criteria for LBB capture. Mean follow-up time was 17.8±6.9 months. LBB capture threshold at implant was 0.65±0.27 mV@0.5ms and 0.71±0.35 mV@0.5ms at 2-year follow-up (n=166). Left ventricular ejection fraction were improved in QRS≥120ms and &lt;120ms groups (60.62±14.22% vs. 63.95±11.29 %, p&lt;0.001; 49.77±17.58 % vs. 58.58±12.79 %, p&lt;0.001; respectively). The number of patients with moderate and sever tricuspid regurgitation decreased at 1-year (120 to 66;28 to 16; respectively). Permanent right bundle branch injury occurred in 55 (8.9%) patients. LBB capture threshold increased greater than 2 V in 6 patients, loss of capture in 2 patients, two lead dislodgements requiring operative revision within 1 month after implantation during 2-years follow-up. Conclusions: Feasibility and safety of LBBP were confirmed by this large sample size and long-term follow-up study. It is a reliable physiologic method for standards pacing indications.
113P Efficacy of oral etoposide associated with trastuzumab in HER2-positive metastatic breast cancer: Results from the Institut Curie’s database
Authors: C. Chalumeau, J-Y. Pierga, G. Pierron, S. Ballet, S. Nasr, A. Vincent-Salomon, P. Vuagnat, A. Bellesoeur, M. Carton, F.C. Bidard, F. Lerebours
Journal: Annals of Oncology (2021)
An investment case for the prevention and management of rheumatic heart disease in the African Union 2021–30: a modelling study
Authors: Matthew M Coates, Karen Sliwa, David A Watkins, Liesl Zühlke, Pablo Perel, Florence Berteletti, Jean-Luc Eiselé, Sheila L Klassen, Gene F Kwan, Ana O Mocumbi, Dorairaj Prabhakaran, Mahlet Kifle Habtemariam, Gene Bukhman
Journal: The Lancet Global Health (2021)

Despite declines in deaths from rheumatic heart disease (RHD) in Africa over the past 30 years, it remains a major cause of cardiovascular morbidity and mortality on the continent. We present an investment case for interventions to prevent and manage RHD in the African Union (AU).We created a cohort state-transition model to estimate key outcomes in the disease process, including cases of pharyngitis from group A streptococcus, episodes of acute rheumatic fever (ARF), cases of RHD, heart failure, and deaths. With this model, we estimated the impact of scaling up interventions using estimates of effect sizes from published studies. We estimated the cost to scale up coverage of interventions and summarised the benefits by monetising health gains estimated in the model using a full income approach. Costs and benefits were compared using the benefit-cost ratio and the net benefits with discounted costs and benefits.Operationally achievable levels of scale-up of interventions along the disease spectrum, including primary prevention, secondary prevention, platforms for management of heart failure, and heart valve surgery could avert 74 000 (UI 50 000-104 000) deaths from RHD and ARF from 2021 to 2030 in the AU, reaching a 30·7% (21·6-39·0) reduction in the age-standardised death rate from RHD in 2030, compared with no increase in coverage of interventions. The estimated benefit-cost ratio for plausible scale-up of secondary prevention and secondary and tertiary care interventions was 4·7 (2·9-6·3) with a net benefit of $2·8 billion (1·6-3·9; 2019 US$) through 2030. The estimated benefit-cost ratio for primary prevention scale-up was low to 2030 (0·2, <0·1-0·4), increasing with delayed benefits accrued to 2090. The benefit-cost dynamics of primary prevention were sensitive to the costs of different delivery approaches, uncertain epidemiological parameters regarding group A streptococcal pharyngitis and ARF, assumptions about long-term demographic and economic trends, and discounting.Increased coverage of interventions to control and manage RHD could accelerate progress towards eradication in AU member states. Gaps in local epidemiological data and particular components of the disease process create uncertainty around the level of benefits. In the short term, costs of secondary prevention and secondary and tertiary care for RHD are lower than for primary prevention, and benefits accrue earlier.World Heart Federation, Leona M and Harry B Helmsley Charitable Trust, and American Heart Association.
Early Prediction of Cardiac Complications in Acute Myocarditis by Means of Extracellular Volume Quantification With the Use of Dual-Energy Computed Tomography
Authors: Salim A. Si-Mohamed, Anaelle Congi, Arthur Ziegler, Danka Tomasevic, Valerie Tatard-Leitman, Thomas Broussaud, Sara Boccalini, Mourad Bensalah, Anne-Sophie Rouvière, Eric Bonnefoy-Cudraz, Thomas Bochaton, Loic Boussel, Philippe C. Douek
Journal: JACC. Cardiovascular imaging (2021)
Abstract P126: Identifying Successful Predictors Of Body Fat Reduction In The Dietfits Trial
Authors: Anthony Crimarco, Priya Fielding-Singh, Matt Landry, Christopher D Gardner
Journal: Circulation (2021)

Background: Reducing excess body fat is important for overall health, but individual success at reducing body fat varies considerably. Because dietary modification plays a key role in reducing body fat and maintaining a healthy body weight, there has been speculation if one particular dietary pattern is superior to another for losing weight. Previously we reported no significant differences in the effectiveness of either a low-carbohydrate diet or a low-fat diet for weight loss in the DIETFITs Trial. However, there is less literature that has specifically focused on body fat reduction. Therefore the purpose of this study was to assess if 12-month dietary changes were associated with body fat reduction. Methods: Participants were men and women with overweight or obesity that participated in the DIETFITS trial, a randomized clinical trial comparing the effectiveness of a healthy low-fat diet to a healthy low-carbohydrate diet for weight loss. The primary outcome was body fat percent loss, which was measured with dual-energy x-ray absorptiometry (DEXA) scans. Demographic information was collected from online surveys at baseline, dietary data were assessed from participants 24-hour recalls, and physical activity was assessed with the Stanford Seven-Day Physical Activity Recall questionnaire. Linear regression models were conducted to assess the association between changes in energy intake, dietary fat, and carbohydrates with body fat reduction, while controlling for demographic variables and physical activity. Results: Data were available for 272 participants with DEXA scans and dietary data. In the main model both baseline physical activity (coef = -0.26, p = 0.016) and changes in physical activity (coef = -0.36, p &lt; 0.01) were significantly associated with body fat reduction. When stratified by dietary assignment, changes in physical activity remained significant for each group (low-carb group: coef = -0.30, p = 0.002 and low-fat group coef = -0.35, p = 0.006), while changes in dietary fat, as a percentage of energy intake, was associated with body fat reduction in the low-fat group only (coef = 0.15, p = 0.006). Race was also significantly associated with body fat reduction in all models, indicating non-White participants gained more body fat at the end of the intervention compared to Whites. Conclusions: The reduction in body fat appears to be mostly driven from participants increasing their physical activity levels. Identifying other predictors of body fat reduction warrant further study.
Targeting Of Chronic Lymphocytic Leukemia B Cells With a Humanized Monoclonal Antibody Specific For ROR1
Authors: George F. Widhopf, Bing Cui, Christina C.N. Wu, Jian Yu, Fitzgerald Lao, Rommel Tawatao, Rongrong Wu, Esther Avery, Anil Sadarangani, Charles Prussak, Catriona HM Jamieson, Dennis A. Carson, Thomas J. Kipps
Journal: Blood (2013)
103P Long-term results and bone-protective effect of everolimus added to letrozole and ovarian function suppression for premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated analysis of the LEO study
Authors: H. Jeong, J.H. Jeong, J.E. Kim, J-H. Ahn, K.H. Jung, S-J. Koh, J. Cheon, J.H. Sohn, G.M. Kim, K.S. Lee, S.H. Sim, I.H. Park, S-B. Kim
Journal: Annals of Oncology (2021)
Abstract 17454: The Effect of Catheter Ablation on Coronary Sinus Cycle Length in Persistent Atrial Fibrillation
Authors: Ghaith Zaatari, Jorge Bohorquez, Raul Mitrani, Jason Ng, Justin Ng, Harold Rivner, Alex Velasquez, Litsa Lambrakos, Rishi Arora, Jeffrey J Goldberger
Journal: Circulation (2020)

Background: While pulmonary vein isolation (PVI) for treatment of persistent atrial fibrillation (PeAF) is successful in approximately 50%, acute termination of PeAF is rarely observed. Prolongation of cycle length (CL) by 10% is often utilized as an indicator of successful catheter ablation (CA). Objective: To evaluate coronary sinus (CS) cycle length (CL) before and after CA for PeAF. Methods: CA for PeAF was performed in 31 patients (24males, age 63±9 yrs, CHA2DS2-VASc 2.3±1.7, LVEF 49±10%) with PVI, with 4 (13%) also having posterior wall isolation. A multielectrode catheter was placed in the CS and maintained throughout the procedure. CS electrograms were recorded for 10 seconds prior to CA and after completion of CA. No patient reverted to sinus rhythm during CA. CS CL was determined using customized software for activation detection and verified visually, excluding ventricular activation and low quality signals (n=3). The shortest CL among the recording electrodes was used for analysis. Results: CS CL pre- and post-CA were 182.4±23.0 and 191.6± 29.9 ms (p= 0.04) with change from baseline of 5.4±12.7%. The figure shows the histogram for change in CS CL from baseline. Only 7/28 (25%) of patients had CS CL prolongation &gt;10%. Of ten patients who were free of AF off anti-arrhythmic drugs at 1 year, CS CL increased 4.0±6.1%; 2/10 had CS CL prolongation &gt;10%. Of 6 patients with recurrent AF, CS CL increased 13.8±20.7%; 4/6 had CS CL prolongation &gt;10%. Conclusion: Our data demonstrate that CS CL prolongation &gt;10% is not a useful marker of outcomes in patients undergoing catheter ablation for PeAF. This highlights the need to identify other indicators of acute ablation success.
Abstract 16841: Coaxial Anti-Inflammatory Scaffold Preserves the Phenotype of MSCs Under Stress
Authors: Naveen Nagiah, Federico Franchi, Michaela Olthoff, Karen Peterson, Martin Rodriguez-Porcel
Journal: Circulation (2020)

Introduction: Myocardial infarction is an inflammatory condition that leads to scar deposition and cardiac remodeling. Stem cells (SC) are an alternative to prevent cardiac remodeling, but have poor survival after transplanted to an pro-inflammatory ischemic myocardium. Polymeric biocompatible scaffolds are biomaterials that can improve SC retention and survival, with the goal to improve regional cardiac function. Methods: We electrospun fibers of a) uniaxial polycaprolactone (PCL) and b) coaxial PCL (core) and gelatin methacrylate (sheath), an anti-inflammatory substance. We first tested the SC retention of each scaffold. Then, adipose derived mesenchymal SCs (MSCs) were co-cultured with M1 macrophages (pro-inflammatory) with and without scaffold and we measure the expression of inflammatory-related genes (RT-PCR). Lastly, PCL+GelMA scaffolds with and without MSCs (3.5x10 3 MSCs) were implanted after myocardial ischemia/reperfusion (IR) and followed for 2 weeks. Results: The average diameter of PCL and PCL+GelMA fibers were 730±40nm and 1110±50nm, respectively. PCL+GelMA scaffolds increased MSCs adhesion compared to PCL (absorbance: 0.09±.03 for PCL and 0.24±0.02 for coaxial, p&lt;0.05). Figure A shows that MSCs in presence of M1 macrophages had a significant increase in inflammatory genes, which was significantly ameliorated in the presence of GelMA. In preliminary animal studies (n=1-4), MSCs delivered in a PCL+GelMA scaffold had partial preservation of regional function parameteres compared to IR only or IR+PCL+GelMA (no MSCs) (Figure B). Conclusion: Coaxially PCL+gelMA scaffolds attenuate the pro-inflammatory milieu of MSCs under ischemic-like conditions, and may improve regional cardiac remodeling.
Basic : Diagnostic value of simplified criteria in korean patients with autoimmune hepatitis (초)
Authors: Bo Hyun Kim, Yoon Jun Kim, Sang Youn Hwang, Sook Hyang Jeong, Won Young Tak, Sang Hoon Ahn, Youn Jae Lee, Eun Uk Jung, Jung Il Lee, Jong Eun Yeon, Jae Seok Hwang, Soon Ho Um, Yeon Seok Seo
Journal: Clinical and Molecular Hepatology (2011)
DACH1 protects podocytes from experimental diabetic injury and modulates PTIP-H3K4Me3 activity
Authors: Aili Cao, Jianhua Li, Morad Asadi, John M. Basgen, Bingbing Zhu, Zhengzi Yi, Song Jiang, Tomohito Doke, Osama El Shamy, Niralee Patel, Paolo Cravedi, Evren U. Azeloglu, Kirk N. Campbell, Madhav Menon, Steve Coca, Weijia Zhang, Hao Wang, Ke Zen, Zhihong Liu, Barbara Murphy, John C. He, Vivette D. D’Agati, Katalin Susztak, Lewis Kaufman
Journal: Journal of Clinical Investigation (2021)

Dachshund homolog 1 (DACH1), a key cell-fate determinant, regulates transcription by DNA sequence–specific binding. We identified diminished Dach1 expression in a large-scale screen for mutations that convert injury-resistant podocytes into injury-susceptible podocytes. In diabetic kidney disease (DKD) patients, podocyte DACH1 expression levels are diminished, a condition that strongly correlates with poor clinical outcomes. Global Dach1 KO mice manifest renal hypoplasia and die perinatally. Podocyte-specific Dach1 KO mice, however, maintain normal glomerular architecture at baseline, but rapidly exhibit podocyte injury after diabetes onset. Furthermore, podocyte-specific augmentation of DACH1 expression in mice protects from DKD. Combined RNA sequencing and in silico promoter analysis reveal conversely overlapping glomerular transcriptomic signatures between podocyte-specific Dach1 and Pax transactivation-domain interacting protein (Ptip) KO mice, with upregulated genes possessing higher-than-expected numbers of promoter Dach1-binding sites. PTIP, an essential component of the activating histone H3 lysine 4 trimethylation (H3K4Me3) complex, interacts with DACH1 and is recruited by DACH1 to its promoter-binding sites. DACH1-PTIP recruitment represses transcription and reduces promoter H3K4Me3 levels. DACH1 knockdown in podocytes combined with hyperglycemia triggers target gene upregulation and increases promoter H3K4Me3. These findings reveal that in DKD, diminished DACH1 expression enhances podocyte injury vulnerability via epigenetic derepression of its target genes.
Abstract MP38: Longitudinal Population-Level Changes In Resting Heart Rate During The COVID-19 Pandemic: Impact Of Changes In Sleep, Circadian, And Physical Activity Variables
Authors: Naghmeh Rezaei, Michael A Grandner
Journal: Circulation (2021)

Introduction: Population-level objective estimates of changes in health metrics over the course of the COVID-19 pandemic are sparse. This study evaluated change in resting heart rate (RHR) determined by optical plethysmography and relationships to changes in other lifestyle health behaviors (sleep and activity). Methods: Data were obtained from N=197,988 Fitbit users who wore their heart-rate enabled Fitbit device to sleep and had detected sleep stages at least 10 days in the month of January, the baseline period; and synced their devices at least once in the last 10 days of April. In addition, potential participants needed to reside in one of 6 target cities: Chicago, Illinois; Houston, Texas; Los Angeles, California; San Francisco, California; New York City, New York; and Miami, Florida. Users who met these criteria were randomly selected. Daily RHR, sleep duration (minutes), sleep duration variability (standard deviation), bedtime, step count, and active minutes were estimated by the device. Differences between January (before the pandemic) and April (peak of stay-at-home orders) was computed. Correlations between change in RHR and change in other variables were evaluated, stratified by age and sex. Results: For all age groups, in both men and women, mean RHR declined from January to April by about 1bpm, with the highest reductions in the youngest adults (all p&lt;1x10 -100 ). In general, across both genders and all age groups, reductions in RHR were correlated with greater sleep duration, delaying bedtime, reduced sleep variability, and more active minutes. Steps were also associated in younger (but not older) adults. Results for ages 18-29 and &gt;=65 are displayed in the Table. Discussion: During the COVID-19 pandemic, RHR decreased robustly but very slightly. Reductions in RHR were correlated with improvements in other health behaviors (sleep and activity). Causal relationships could not be evaluated, but future studies may explore whether even small changes in health behaviors can measurably impact population RHR.
Genomic and Outcome Analyses of Philadelphia Chromosome-like (Ph-like) NCI Standard Risk B-Acute Lymphoblastic Leukemia (SR B-ALL) Patients Treated on Children's Oncology Group (COG) AALL0331
Authors: Shalini C. Reshmi, Richard C. Harvey, Kathryn G. Roberts, Eileen Stonerock, Yunfeng Dai, I-Ming L. Chen, Marc Valentine, Yu Liu, Yongjin Li, Jinghui Zhang, Debbie Payne-Turner, Meenakshi Devidas, Nyla A. Heerema, Andrew Carroll, Elizabeth A. Raetz, Michael Borowitz, Brent Wood, Anne Angiolillo, Michael J. Burke, Wanda Salzer, Patrick A. Zweidler-McKay, Karen R. Rabin, Leonard A. Mattano, Kelly Maloney, William L. Carroll, Mignon L. Loh, Charles G. Mullighan, Cheryl L. Willman, Julie M. Gastier-Foster, Stephen P. Hunger
Journal: Blood (2017)
Chloramphenicol eye drops: GPs criticise lack of guidance over use in under 2s
Authors: Zosia Kmietowicz
Journal: BMJ (2021)

GPs have been left with no guidance on the use of chloramphenicol eye drops for children aged under 2 years despite the UK’s drug regulator knowing for three years that the products were no longer recommended for this age group.

The licence for chloramphenicol eye drops was changed in 2017 after the European Medicines Agency said that products delivering more than the permitted daily exposure to boron should be avoided because of concerns about effects on future fertility. For children under 2 the maximum permitted daily exposure is 1mg a day.1 Manufacturers were given three years to change their product information to say that chloramphenicol …
Targeting Epigenetic and Posttranscriptional Gene Regulation by PSF Impairs Hormone Therapy–Refractory Cancer Growth
Authors: Ken-ichi Takayama, Teruki Honma, Takashi Suzuki, Yasumitsu Kondoh, Hiroyuki Osada, Yutaka Suzuki, Minoru Yoshida, Satoshi Inoue
Journal: Cancer Research (2021)

Abstract RNA-binding protein PSF functions as an epigenetic modifier by interacting with long noncoding RNAs and the corepressor complex. PSF also promotes RNA splicing events to enhance oncogenic signals. In this study, we conducted an in vitro chemical array screen and identified multiple small molecules that interact with PSF. Several molecules inhibited RNA binding by PSF and decreased prostate cancer cell viability. Among these molecules and its derivatives was a promising molecule, No. 10–3 [7,8-dihydroxy-4-(4-methoxyphenyl)chromen-2-one], that was the most effective at blocking PSF RNA-binding ability and suppressing treatment-resistant prostate and breast cancer cell proliferation. Exposure to No. 10–3 inhibited PSF target gene expression at the mRNA level. Treatment with No. 10–3 reversed epigenetically repressed PSF downstream targets, such as cell-cycle inhibitors, at the transcriptional level. Chromatin immunoprecipitation sequencing in prostate cancer cells revealed that No. 10–3 enhances histone acetylation to induce expression of apoptosis as well as cell-cycle inhibitors. Furthermore, No. 10–3 exhibited antitumor efficacy in a hormone therapy–resistant prostate cancer xenograft mouse model, suppressing treatment-resistant tumor growth. Taken together, this study highlights the feasibility of targeting PSF-mediated epigenetic and RNA-splicing activities for the treatment of aggressive cancers. Significance: This study identifies small molecules that target PSF–RNA interactions and suppress hormone therapy–refractory cancer growth, suggesting the potential of targeting PSF-mediated gene regulation for cancer treatment.
Abstract 16099: Predictors of Cardiovascular Implantable Electronic Device-dependence at Long-term Follow-up After Alcohol Septal Ablation in Hypertrophic Cardiomyopathy Patients
Authors: Weeranun D Bode, Michael F Bode, Megan Zhao, Rahul Sakhuja, Michael A Fifer, Theofanie Mela
Journal: Circulation (2020)

Introduction: The most common complication of alcohol septal ablation (ASA) is periprocedural high grade AV block (HGAVB). No long-term follow-up of cardiovascular implantable electronic device (CIED) utilization after ASA has been reported. Hypothesis: Pacemaker dependence on long-term follow up can be predicted by ECG or procedural characteristics. Methods: We analyzed all patients with hypertrophic cardiomyopathy who underwent ASA from December 1998 to December 2019 at our institution and received their first CIED within 30 days after ASA for HGAVB. All available follow-up interrogations were reviewed. CIED dependence was defined as ventricular pacing of ≥5%. CIED programming was determined by the patients’ cardiologists' discretion. Results: A total of 103 patients with hypertrophic cardiomyopathy underwent ASA. The average follow up duration was 10.1 years. Within 30 days after ASA, a total 25 patients received a CIED for HGAVB. On long term follow-up 16 patients (64%) were found to be CIED-dependent. Baseline characteristics, including pre and post-ASA ECG, were not significantly different between dependent and non-dependent patients (Table). The only predictor for CIED dependence was &gt;1 ml of alcohol injected during ASA (OR 6.0, p&lt;0.046). Conclusions: CIED implantation after ASA is common. Almost two thirds of patients who received CIED for postprocedural HGAVB were CIED-dependent on long term follow up. CIED dependence can be predicted by amount of injected alcohol &gt;1 ml during ASA.